StockNews.com Begins Coverage on Catalent (NYSE:CTLT)

StockNews.com initiated coverage on shares of Catalent (NYSE:CTLT) in a research report issued to clients and investors on Friday. The brokerage set a “hold” rating on the stock.

Several other brokerages also recently weighed in on CTLT. Robert W. Baird restated a “neutral” rating and set a $63.50 price target on shares of Catalent in a report on Tuesday, September 24th. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Finally, William Blair reiterated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Eight research analysts have rated the stock with a hold rating, According to data from MarketBeat, Catalent has a consensus rating of “Hold” and a consensus target price of $63.40.

Catalent Stock Performance

Shares of Catalent stock opened at $63.48 on Friday. Catalent has a fifty-two week low of $41.15 and a fifty-two week high of $63.50. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. The firm has a market capitalization of $11.52 billion, a price-to-earnings ratio of -28.09, a PEG ratio of 2.70 and a beta of 1.15. The stock has a 50 day moving average of $60.76 and a 200 day moving average of $59.49.

Catalent (NYSE:CTLT) last posted its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same quarter last year, the business posted ($0.10) EPS. The firm’s revenue for the quarter was up 4.2% on a year-over-year basis. As a group, research analysts predict that Catalent will post 0.78 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Michelle R. Ryan sold 2,800 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the sale, the director now directly owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. The trade was a 20.54 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.31% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Catalent

A number of institutional investors have recently modified their holdings of CTLT. Brooklyn Investment Group acquired a new position in shares of Catalent in the third quarter valued at approximately $31,000. Sentry Investment Management LLC acquired a new stake in shares of Catalent in the 3rd quarter worth $53,000. Longfellow Investment Management Co. LLC boosted its holdings in shares of Catalent by 45.7% in the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after acquiring an additional 305 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. increased its stake in shares of Catalent by 57.5% during the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company’s stock worth $72,000 after acquiring an additional 431 shares during the period. Finally, Intact Investment Management Inc. acquired a new stake in Catalent in the third quarter valued at about $73,000.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.